We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Celgene Says FDA Panel Won’t Review Pomalidomide
Celgene Says FDA Panel Won’t Review Pomalidomide
October 4, 2012
Celgene said that a Food and Drug Administration panel will not review its multiple myeloma drug pomalidomide in November. Businessweek
